These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Author: Falkson CI, Falkson HC, Falkson G.
    Journal: Invest New Drugs; 1989 Jul; 7(2-3):261-7. PubMed ID: 2507474.
    Abstract:
    One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX). Mesna was used as urothelial protector. With mesna, urothelial toxicity was moderate, and single doses of up to 7 g/m2 could be administered without intolerable urotoxicity. Leukopenia was the dose-limiting factor in this study. Unexpected pulmonary edema occurred in 3 patients. Therapeutic results were disappointing. A malignancy identified in this study that warrants further investigation with IFX and mesna, is malignant mesothelioma.
    [Abstract] [Full Text] [Related] [New Search]